Wereport here a very rare case of a nephrotic patient who developed acute myelogenous leukemia (AML, M2) 8 months after receiving cyclosporin A (CsA) therapy. A 30-year-old manwith nephrotic syndrome had been taking diphenylhydantoin (DPH, 300 mg/day) for 6 years for treatment of convulsion and then received treatment of prednisolone and CsA (75 mg/day) for a nephrotic syndrome.
Introduction
Cyclosporin A (CsA) was first marketed as an immunosuppressive agent in transplantations and recently has been proven to be effective in the treatment of renal diseases. Although CsA does not have carcinogenic or mutagenic potential (1, 2) , the use of the drug has been associated with an increased risk of malignancies due to its immunosuppressive properties (3) . We report here a very rare case of a nephrotic patient whodeveloped acute myelogenous leukemia (AML)8 months after receiving CsA therapy.
Case Report
The patient was a 30-year-old man with a history of several relapses of nephrotic syndrome beginning when he was 5 years old. To control the convulsions due to a traffic accident at the age of 24, he had received diphenylhydantoin (DPH, 300 mg/ day) for 6 years.
In February 1995, when he was 29 years old, he was transferred to our hospital for the treatment of nephrotic syndrome. His nephrotic syndromehad been well controlled for a while thereafter, but recurred when prednisolone (PSL) was tapered to 10 mg/day. On May 10, 1996, CsA (75 mg/day) was added to the treatment with PSL (20 mg/day). At the time, laboratory tests showed: hemoglobin 16.9 g/dl, hematocrit (Ht) 50.2%, platelets 1 33,000/|Lil, and white blood corpuscles (WBC) 5,900/ jllI with 70% neutrophil with normal morphology and without atypical cells. On hemogramstaken monthly on an outpatient basis for one year, no peripheral blood abnormalities, such as anemia, leukocytopenia, thrombocytopenia, or circulating immature cells, were detected. In September 1996, 4 months after the beginning of CsA therapy, 1.0% of myeloblasts appeared in his peripheral blood. The percentage of myeloblasts gradually increased. On December 4, after 7 months of CsA therapy, his blood cell counts revealed Ht of47.6%, a WBCof 5,lOO/^il with 10% myeloblasts and 141 ,000/|iil platelets. Bone marrow examination disclosed normocellular bone marrowwith 30% myeloidatypical cells. Because an association was suspected between the increased abnormal cells and CsAtherapy, on December 4 the CsA therapy was discontinued. On January 29, 1997, his blood cell counts revealed a WBCof 6,400/|al, with 39%myeloid blasts, mean corpuscular volume 102.5 fl, platelets 121,000/|Lil, and hemoglobin 16.0 g/dl. Serum concentrations of CsA were 174-284 ng/ml 2 hours after taking it and 7 ng/ml at its trough. The second bone marrow aspiration with flow cytometric evaluation and a biopsy confirmed a diagnosis of AML(M2, according to the FABclassification), showing hypercellular bone marrow with 60%leukemic cells. Chromosomal analysis showed no abnormality. The patient declined to be admitted to the hospital. The level of peripheral myeloblasts rose to 72%with time, and Ht and platelets fell gradually to 42.2% and 92,000/|Lil, respectively, by July 1997, when he was finally admitted to our hospital. He received in-Cyclosporine and Leukemia 
Discussion
Penn has shown, using data from the Cincinnati Transplant Tumor Registry, that leukemia in general represents about 3% of tumors arising after conventional immunosuppressivenonCsA therapy, but less than 1% after CsA therapy (3). Only 2 patients whodeveloped acute myelogenousleukemia following treatment with CsA have been previously reported. One was a renal transplant patient who developed AML5 years after treatment with CsAand azathioprine (4). The other was a rheumatoid arthritis patient who developed AML4 months after the beginning of CsA therapy (5). Our patient developed AMLa remarkably short time after CsAtherapy began, similar to the latter case.
According to Penn, the most commontumors in patients with CsAwere non-Hodgkin's lymphoma,which accounted for 38%of the total in such patients, compared with 12%in patients who had received conventional non-CsA immunosuppressant; furthermore, this type of tumor in CsA-treated patients appeared a remarkably short time after the start of treatment: an average of 10 months, comparedwith an average of 43 months after conventional therapy (3) . In the present case, it is difficult to explain the association between the development of AMLand CsA therapy, because the interval between these events was so short.
In experimental studies, it was reported that cyclosporin did not cause cancer in the absence of an initiating event (e.g., chemical mutagen) (6) . Hojo et al (7) described a tumor growthpromoting effect of CsAin immunodeficient mice. Hermanet al (8) suggested that immunosuppressive therapy might interfere with DNArepair and thus contribute to the increased cancer incidence in transplant patients. Although the tumor-promoting effects of CsAseen in this laboratory setting should not be extrapolated to clinical situations, knowledgeof an unwarranted effect of CsA in the induction, growth or behavior of neoplasm would be of utmost importance to clinicians and patients.
Indeed, it is rarely reported that therapy with CsAwas solely responsible for the development of neoplasm. In the long-term follow-up of patients with aplastic anemia, the development of myelodysplastic syndromeor acute myelogenous leukemia has been observed. In a study by Ohara et al (9) , these clonal disorders were found only in children who had received both CsA and recombinant human granulocyte colony-stimulating factor therapy. The present case had nephrotic syndrome. The association of nephrotic syndrome with neoplastic disease is well known, although carcinomas and lymphomas are common (10) . The patient also received DPH,of which immunosuppressive effects and increased risk of malignant lymphomas have been reported (ll, 12) . Wethink that the risk of this nephrotic patient developing AMLmay be facilitated by synergistic or additive immunosuppressiveeffects of these two agents. A higher frequency of malignancy has been feared for patients with rheumatoid arthritis and psoriasis, and autoimmune diseases intrinsically increase the risk of neoplasm such as lymphoma (13) . However,as moreexperience is gained with cyclosporin in these fields, there is increasing evidence that the development of cancer is not a great concern, at least whencyclosporin is administered at low doses for intermittent periods and without the concomitant use of other immunosuppressive drugs (14, 15) . The hypothesis of cyclosporin promoting neoplasm in nephrotic patients at risk must also be tested with appropriate epidemiological studies such as cohort or case-control studies. Unfortunately, there have been no data on the best way to administer and monitor CsAto prevent the development of neoplasm. Our experience suggests that weshould ask a patient with nephrotic syndrome detailed questions about his or her drug histories before the start of CsA therapy, and avoiding combination therapies with other immunosuppressantsmay reduce the risk of malignancy.
